Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 28.38B +71.3% |
| Revenue (ttm) | 8.78B +0.3% |
| Net Income | 730.53M -45.5% |
| EPS | 4.94 -46.1% |
| Shares Out | n/a |
| PE Ratio | 38.85 |
| Forward PE | 16.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 183.02 |
| Previous Close | 186.38 |
| Day's Range | 183.02 - 183.02 |
| 52-Week Range | 114.55 - 193.00 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen price target raised to $245 from $225 at Piper Sandler
Piper Sandler raised the firm’s price target on Biogen (BIIB) to $245 from $225 and keeps an Overweight rating on the shares. The firm cites post-Q2 model updates for the…
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous formulation, the anti-amyloid beta protofibril antibody Leqembi, as a...
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer's Disease Approved in China
The First and Only Anti-Amyloid Therapy in China that Enables At-Home Administration for Alzheimer's Disease, a Progressive Neurodegenerative Disease The First and Only Anti-Amyloid Therapy in China t...
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
Stoke Therapeutics (STOK) and Biogen (BIIB) announced presentations of data at the 16th European Epilepsy Congress September 5-9 in Athens. These data support the potential of zorevunersen as a first-...
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen–
Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd.
Biogen, Eisai announce positive recommendation for Leqembi in Canada
Eisai (ESAIY) and Biogen Canada (BIIB) announced receipt of the Canada’s Drug Agency’ final positive recommendation supporting public reimbursement for Leqembi, for eligible Canadians living with mild...
Biogen price target raised to $260 from $240 at RBC Capital
TRBC Capital raised the firm’s price target on Biogen (BIIB) to $260 from $240 and keeps an Outperform rating on the shares. The firm says the litifilimab data in Q4…
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
Eisai (ESAIY) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer’s disease in adults with mild c...
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
Eisai (ESAIY) and Biogen (BIIB), announced that once weekly lecanemab-irmb subcutaneous injection is now available in the U.S. for initiation therapy for early Alzheimer’s disease in adults with mild ...
LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) LEQEMBI IQLIK is the first-of-its-kind anti-amyloi...
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 /PRNewsw...
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform with a $300 price target
Wolfe upgrades Biogen to Outperform on late-stage pipeline
Wolfe Research upgraded Biogen (BIIB) to Outperform from Peer Perform with a $300 price target The readouts for both litifilimab and felzartamab are “relative de-risked” and underappreciated at curren...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Biogen completes acquisition of RayThera
Biogen (BIIB) announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. “The ac...
Biogen Completes Acquisition of RayThera Inc.
CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on dis...
Biogen price target raised to $241 from $221 at Mizuho
Mizuho analyst Salim Syed raised the firm’s price target on Biogen (BIIB) to $241 from $221 and keeps an Outperform rating on the shares.
Biogen price target raised to $215 from $200 at Citi
Citi raised the firm’s price target on Biogen (BIIB) to $215 from $200 and keeps a Neutral rating on the shares. The firm updated models in the biotechnology space post…
Biogen price target raised to $231 from $222 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Biogen (BIIB) to $231 from $222 and keeps an Equal Weight rating on the shares.
Biogen price target raised to $251 from $237 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Biogen (BIIB) to $251 from $237 and keeps a Buy rating on the shares. The firm revisited its penetration assumption across Leqembi,…
Biogen price target lowered to $240 from $242 at RBC Capital
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $240 from $242 and keeps an Outperform rating on the shares. The company reported a very solid commercial quarter,…
Biogen price target raised to $240 from $225 at UBS
UBS raised the firm’s price target on Biogen (BIIB) to $240 from $225 and keeps a Buy rating on the shares.
Biogen price target raised to $215 from $201 at Wedbush
Wedbush analyst Laura Chico raised the firm’s price target on Biogen (BIIB) to $215 from $201 and keeps a Neutral rating on the shares. Overall, the firm sees a solid…
Biogen Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, driven by the expanding growth portfolio and successful integration of Apellis products. The company raised its full-year guidance, highlighted robust late-stage pipeline progress, and expects continued top- and bottom-line growth, with key data readouts and product launches ahead.